Skip to main content
. Author manuscript; available in PMC: 2022 Jul 6.
Published in final edited form as: Adv Healthc Mater. 2021 Dec 10;11(3):e2102276. doi: 10.1002/adhm.202102276

Table 2. PEG-RGD hydrogel formulations and elastic modulus measurements.

In the Table is reported the comparison of stiffness of PEG-RGD Hydrogel formulations achieved with the synthesis procedure used in the present work (column 4) and as reported in literature[35] (column 5), with the highest RGD molar concentration (3mM). The latter is achieved by pre-reacting the RGD containing peptide with NB functionalities and then by UV-crosslinking. In our procedure all peptides (the one containing RGD and the crosslinking peptide) are reacted simultaneously, allowing a more homogeneous distribution of RGD containing peptide among 8ArmPEG macromers (i.e. avoiding possible “saturation” of the NB terminated arms) and therefore achieving a more efficient crosslinking degree.

PEG-RGD Hydrogel Molar ratio 1Cys/NB 2NB-8ArmPEG wt% 3Elastic modulus PEG-RGD 3*Elastic modulus PEG-RGD
PEG-RGD1 0.4/1 4.7 0.30 ± 0.13 0.02 ± 0.08
PEG-RGD2 0.5/1 5.0 0.87 ± 0.13 0.11 ± 0.01
PEG-RGD3 0.6/1 5.2 1.17 ± 0.31 0.20 ± 0.03
PEG-RGD4 0.7/1 5.5 2.63 ± 0.38 0.71 ± 0.08
PEG-RGD5 0.8/1 9 7.71 ± 0.38 1.62 ± 0.03
PEG-RGD6 0.8/1 12.5 13.7 ± 0.48 4.47 ± 0.65
1

Cys=Cysteine terminal group of the crosslinking peptide. RGD concentration is fixed to 3mM

2

NB-8ArmPEG wt% is the weight% of macromer used to synthesize PEG-RGD hydrogels.

3

Stiffness measurements by micropipette aspiration.[40]